This application is in response to RFA MH-03-008 to form a National Cooperative Drug Discovery Group for the Treatment of Mood Disorders or Nicotine Addiction (NCDDG-MD/NA) to work or innovative drug discovery for these two disorders, and the development and validation of a putative new animal model of antidepressant activity. This project will involve an academic partner, The Scripps Research Institute, La Jolla, California, and an industrial partner, Novartis Pharma AG, Basel Switzerland. The pharmacological approach proposed is the development of gamma-aminobutyric acid B (GABAB) receptor positive modulators as antidepressants and/or aids to smoking cessation.
Specific Aim 1 will involve the synthesis and refinement of GABAB receptor positive modulators with good selectivity for the GABAB receptor.
Specific Aim 2 will involve experiments characterizing these (GABAB positive modulators biochemically in human, rat and mouse GABAB receptor assays. Pharmacokinetics, brain penetration, and binding affinities for other receptors and channels will also be evaluated.
Specific Aim 3 will assess the effects of these compounds in nicotine self-administration using both fixed-ratio and progressive ratio schedules of reinforcement in nicotine-dependent rats.
Specific Aim 4 will assess the effects of the compounds in vivo and in animal models of depression. Initial studies will evaluate the potential side-effect profile of these compounds. Subsequent work will evaluate the effects of the compounds in 6 models of antidepressant activity: the forced swim test ill mice and rats, the tail suspension test in mice, the olfactory bulbectomy test in rats, and nicotine and amphetamine withdrawal in rats. The latter test will also provide information about potential therapeutic effects of the compounds on drug withdrawal hypothesized to contribute to relapse. Finally, Specific Aim 5 will attempt to develop and validate a new animal model of depression (7th model) involving olfactory bulbectomy as the inducing condition and brain reward thresholds as the dependent variable, and test putative antidepressant drugs. This integrated multidisciplinary research program focusing on both depression and smoking cessation and capitalizing on the expertise of both Scripps and Novartis scientists will be an innovative approach to the development of new therapeutics for these disorders. |

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01MH069062-02
Application #
6803522
Study Section
Special Emphasis Panel (ZMH1-BRB-S (08))
Program Officer
Foote, Stephen L
Project Start
2003-09-24
Project End
2008-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
2
Fiscal Year
2004
Total Cost
$703,750
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Slattery, David A; Uzunov, Doncho P; Cryan, John F (2016) 11-? hydroxysteroid type 1 knockout mice display an antidepressant-like phenotype in the forced swim test. Acta Neuropsychiatr 28:55-60
Jacobson, Laura H; Sweeney, Fabian F; Kaupmann, Klemens et al. (2016) Differential roles of GABAB1 subunit isoforms on locomotor responses to acute and repeated administration of cocaine. Behav Brain Res 298:12-6
Baksh, Michael M; Kussrow, Amanda K; Mileni, Mauro et al. (2011) Label-free quantification of membrane-ligand interactions using backscattering interferometry. Nat Biotechnol 29:357-60
Kussrow, Amanda; Baksh, Michael M; Bornhop, Darryl J et al. (2011) Universal sensing by transduction of antibody binding with backscattering interferometry. Chembiochem 12:367-70
Slattery, David A; Neumann, Inga D; Cryan, John F (2011) Transient inactivation of the infralimbic cortex induces antidepressant-like effects in the rat. J Psychopharmacol 25:1295-303
D'Souza, Manoranjan S; Markou, Athina (2010) Neural substrates of psychostimulant withdrawal-induced anhedonia. Curr Top Behav Neurosci 3:119-78
Der-Avakian, Andre; Markou, Athina (2010) Withdrawal from chronic exposure to amphetamine, but not nicotine, leads to an immediate and enduring deficit in motivated behavior without affecting social interaction in rats. Behav Pharmacol 21:359-68
Vlachou, Styliani; Markou, Athina (2010) GABAB receptors in reward processes. Adv Pharmacol 58:315-71
Der-Avakian, A; Markou, A (2010) Neonatal maternal separation exacerbates the reward-enhancing effect of acute amphetamine administration and the anhedonic effect of repeated social defeat in adult rats. Neuroscience 170:1189-98
Markou, Athina; Paterson, Neil E (2009) Multiple motivational forces contribute to nicotine dependence. Nebr Symp Motiv 55:65-89

Showing the most recent 10 out of 45 publications